PubMed · 15537058
Technology evaluation: EMD-273063, EMD Lexigen.
Abstract
EMD-273063 is an antibody/cytokine fusion protein comprised of a humanized version of the murine anti-GD2 antibody 14.18 coupled to two molecules of IL-2. It is being developed by EMD Lexigen Research Center Corp (a subsidiary of Merck KGaA) and its sister company, EMD Pharmaceuticals Inc, for the potential treatment of neuroblastoma and melanoma, for which it is in preclinical and phase I clinical trials, respectively.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Ion Niculescu-Duvaz. 2004. Technology evaluation: EMD-273063, EMD Lexigen.. https://pubmed.ncbi.nlm.nih.gov/15537058/
Cite the original work for its findings. Save a collection to share your selection of sources.